Experimental lymphoma therapy tested in tiny early trial
NCT ID NCT05994157
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 1 trial tested a two-step radioimmunotherapy (CD38-SADA and 177Lu-DOTA) in patients with relapsed or refractory non-Hodgkin lymphoma. The goal was to find safe doses and dosing schedules. Only 1 participant was enrolled, and the study was terminated early, so no conclusions about effectiveness can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD38-SADA and 177Lu-DOTA (two-step radioimmunotherapy)
What this could lead to
If it works, this could point toward a new treatment option for patients with hard-to-treat non-Hodgkin lymphoma.
What could go wrong
This was a very early, small phase 1 trial with only 1 participant, and it was terminated early. It is unclear if the approach is safe or effective, and it may not work in larger groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Corewell Health-BAMF Health
Grand Rapids, Michigan, 49503, United States
-
East Carolina University Leo W. Jenkins Cancer Center
Greenville, North Carolina, 27834, United States
-
HonorHealth
Scottsdale, Arizona, 85258, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Stony Brook Cancer Center
Stony Brook, New York, 11794, United States